Last updated: March 6, 2026
What is NDC 72603-0212?
NDC 72603-0212 corresponds to Fetroja (cefiderocol), an antibiotic developed by Shionogi, approved by the FDA in 2019. It is used to treat complicated urinary tract infections, pneumonia, and other serious infections caused by susceptible organisms. Cefiderocol is a novel siderophore cephalosporin that penetrates bacterial cell walls by hijacking iron transport mechanisms.
Market Size and Growth Drivers
Current Market Volume
- The global antibiotic market was valued at approximately USD 52 billion in 2022.
- Cefiderocol's initial market footprint is estimated between USD 300 million and USD 500 million annually since its launch.
- The drug's primary markets include the U.S., Europe, and select Asian countries.
Incidence and Unmet Need
- Primary use cases involve multidrug-resistant (MDR) Gram-negative bacteria, with resistant infections increasing by 10% annually.
- The CDC reports around 300,000 annual cases of complicated urinary tract infections (cUTIs) and pneumonia resistant to standard therapies.
- Cefiderocol targets a niche in treating infections resistant to carbapenems and other β-lactams.
Competitive Landscape
| Drug |
Class |
Approvals |
Market Share (est.) |
Key Differentiator |
| Cefiderocol (Fetroja) |
Siderophore cephalosporin |
2019 (FDA), 2020 (EMA) |
~20-25% |
Novel mechanism, broad spectrum |
| Meropenem-vaborbactam |
Carbapenem + β-lactamase inhibitor |
2017 (FDA) |
~35% |
Proven efficacy against KPC producers |
| Ceftazidime-avibactam |
Cephalosporin + β-lactamase inhibitor |
2015 (FDA) |
~30% |
Activity against resistant strains |
Future Market Drivers
- Rising antibiotic resistance among Gram-negative bacteria.
- Increasing prevalence of healthcare-associated infections.
- Limited pipeline of new antimicrobials for resistant pathogens due to regulatory and scientific challenges.
- Growing adoption of combination therapies and innovative antibiotics.
Price Analysis and Projections
Current Pricing
- The wholesale acquisition cost (WAC) for Fetroja in the U.S. is approximately USD 10,000 - USD 12,000 per treatment course.
- Price varies geographically due to reimbursement policies, with U.S. prices being higher than European or Asian markets.
Cost-Effectiveness and Reimbursement
- The drug's high acquisition cost is balanced against its use in resistant infections with limited alternative therapies.
- Insurers and healthcare systems assess cost-effectiveness based on clinical benefits, resistance profiles, and hospitalization costs.
Price Trends (2023-2028)
| Year |
Estimated Price per Course |
Market Penetration |
Key Influencing Factors |
| 2023 |
USD 11,000 |
15-20% |
Increased use in hospitals due to resistance |
| 2024 |
USD 11,500 |
25-30% |
Expanded indications and hospital adoption |
| 2025 |
USD 12,000 |
40-50% |
Competitive pressure from new agents |
| 2026-2028 |
Stabilization or slight decline |
50-60% |
Entry of biosimilars or generics if approved |
Pricing Assumptions
- The projection assumes increased adoption driven by resistance trends.
- Price adjustments will reflect supply chain costs, insurer negotiations, and competitive landscape evolution.
- International markets will see pricing inflation of 3-5% annually, influenced by local reimbursement policies.
Key Market Considerations
- Regulatory Pathways: Orphan drug designations, Fast Track, and QIDP status in the U.S. may influence pricing and market access.
- Patent Lifetime: Patent protection expiring around 2030 impacts generic entry and price erosion.
- Market Access: Reimbursement negotiations with CMS and international health agencies influence profitability.
- Clinical Development: Ongoing trials for additional indications could expand the market size and justify price adjustments.
Conclusion
Fetroja (NDC 72603-0212) occupies a specialized niche in treating multidrug-resistant Gram-negative infections. The drug's market is expected to grow modestly through increasing resistance and expanding indications, with prices stabilizing around USD 11,000-12,000 per course over the next five years. Competitive pressures and emerging resistance patterns will shape future pricing and market share.
Key Takeaways
- Cefiderocol targets resistant bacterial infections with limited current therapies.
- The U.S. market price hovers around USD 11,000 per course with potential incremental increases.
- Market growth hinges on resistance trends, clinical adoption, and regulatory developments.
- Competition remains significant, especially from established β-lactamase inhibitors.
- Patent protection and regulatory incentives support pricing stability until early 2030s.
FAQs
-
What are the primary competitors to cefiderocol?
Meropenem-vaborbactam and ceftazidime-avibactam are leading competitors, offering broad activity against resistant Gram-negative bacteria.
-
How does resistant bacteria prevalence impact cefiderocol demand?
Rising resistance increases demand as clinicians seek effective options; resistance to other agents drives use of cefiderocol.
-
What factors could influence price declines?
Entry of generics post-patent expiration, increased competition, and decreased resistance levels could lower prices.
-
What are the key markets for cefiderocol?
The U.S., Europe, and select Asian countries, particularly in hospital settings treating resistant infections.
-
How does clinical approval status affect market outlook?
Expanded indications and additional approvals can enhance market size and justify price increases.
References
[1] U.S. Food and Drug Administration (FDA). (2019). Fetroja (cefiderocol) approval letter.
[2] MarketWatch. (2023). Antibiotics market size and forecasts.
[3] CDC. (2021). Antibiotic resistance threats in the United States.
[4] EvaluatePharma. (2022). 2022 World Preview: Outlook to 2027.
[5] Shionogi. (2022). Fetroja (cefiderocol) prescribing information.
